KATIE MANUEL: Open Payments
NPI 1770239303 · SYLACAUGA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,202 in 56 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $477 · 2025 $1,202
Food & beverage: $1,202
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $272 |
| Neurocrine BioSciences, Inc. | 8 | $190 |
| Teva Pharmaceuticals USA, Inc. | 7 | $131 |
| Tris Pharma Inc | 4 | $89 |
| Alkermes, Inc. | 4 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Corium, LLC | 3 | $57 |
Products named: FANAPT, INGREZZA, UZEDY, Dyanavel XR, ARISTADA, CAPLYTA, TRINTELLIX, Auvelity.
Industry payments across AL — which companies pay providers there.
